EA200701195A1 - Содержащие цефалоспорин композиции с наночастицами и с контролируемым высвобождением - Google Patents
Содержащие цефалоспорин композиции с наночастицами и с контролируемым высвобождениемInfo
- Publication number
- EA200701195A1 EA200701195A1 EA200701195A EA200701195A EA200701195A1 EA 200701195 A1 EA200701195 A1 EA 200701195A1 EA 200701195 A EA200701195 A EA 200701195A EA 200701195 A EA200701195 A EA 200701195A EA 200701195 A1 EA200701195 A1 EA 200701195A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- nanoparticles
- cephalosporin
- composition
- cefalosporin
- compositions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5192—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Nanotechnology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Cephalosporin Compounds (AREA)
Abstract
Настоящее изобретение относится к содержащей цефалоспорин композиции, пригодной для лечения и профилактики бактериальной инфекции. В одном из вариантов осуществления композиция содержит наночастицы, содержащие цефалоспорин и по меньшей мере один стабилизатор поверхности. Наночастицы обладают эффективным средним размером менее чем приблизительно 2000 нм. В другом варианте осуществления композиция представляет собой композицию с модифицированным высвобождением, которая при введении пациенту доставляет цефалоспорин бимодальным, мультимодальным или непрерывным образом. Изобретение также относится к лекарственным формам, содержащим такие компоненты, и к способам лечения и профилактики бактериальной инфекции.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/478,891 US20070160675A1 (en) | 1998-11-02 | 2006-06-30 | Nanoparticulate and controlled release compositions comprising a cephalosporin |
Publications (1)
Publication Number | Publication Date |
---|---|
EA200701195A1 true EA200701195A1 (ru) | 2008-02-28 |
Family
ID=38779606
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA200701195A EA200701195A1 (ru) | 2006-06-30 | 2007-06-29 | Содержащие цефалоспорин композиции с наночастицами и с контролируемым высвобождением |
Country Status (14)
Country | Link |
---|---|
US (1) | US20070160675A1 (ru) |
EP (1) | EP1905432A1 (ru) |
JP (1) | JP2008013562A (ru) |
KR (1) | KR20080002689A (ru) |
CN (1) | CN101259106A (ru) |
AU (1) | AU2007202941A1 (ru) |
BR (1) | BRPI0705488A (ru) |
CA (1) | CA2592727A1 (ru) |
EA (1) | EA200701195A1 (ru) |
IL (1) | IL184174A0 (ru) |
MX (1) | MX2007007942A (ru) |
NO (1) | NO20073289L (ru) |
SG (1) | SG138592A1 (ru) |
ZA (1) | ZA200704744B (ru) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8293277B2 (en) * | 1998-10-01 | 2012-10-23 | Alkermes Pharma Ireland Limited | Controlled-release nanoparticulate compositions |
US8236352B2 (en) | 1998-10-01 | 2012-08-07 | Alkermes Pharma Ireland Limited | Glipizide compositions |
US7459283B2 (en) * | 2002-02-04 | 2008-12-02 | Elan Pharma International Limited | Nanoparticulate compositions having lysozyme as a surface stabilizer |
US7198795B2 (en) * | 2000-09-21 | 2007-04-03 | Elan Pharma International Ltd. | In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate of nanoparticulate active agent compositions |
RU2435569C2 (ru) | 2006-03-16 | 2011-12-10 | Трис Фарма, Инк. | Композиции с модифицированным высвобождением, содержащие комплексы лекарственное вещество - ионообменная смола |
AU2010254180B2 (en) | 2009-05-27 | 2015-08-27 | Alkermes Pharma Ireland Limited | Reduction of flake-like aggregation in nanoparticulate active agent compositions |
TR201001417A1 (tr) | 2010-02-25 | 2011-09-21 | Sanovel İlaç San. Ve Ti̇c. A. Ş. | Geliştirilmiş çözünme hızına sahip sefdinir formülasyonu |
US9186642B2 (en) | 2010-04-28 | 2015-11-17 | The Procter & Gamble Company | Delivery particle |
US9993793B2 (en) | 2010-04-28 | 2018-06-12 | The Procter & Gamble Company | Delivery particles |
TR201010859A2 (tr) * | 2010-11-05 | 2012-05-21 | Bi̇lgi̇ç Mahmut | Sefdinir içeren tablet formları. |
US8287903B2 (en) | 2011-02-15 | 2012-10-16 | Tris Pharma Inc | Orally effective methylphenidate extended release powder and aqueous suspension product |
JP6283607B2 (ja) | 2011-04-07 | 2018-02-21 | ザ プロクター アンド ギャンブル カンパニー | ポリアクリレートマイクロカプセルの堆積が増大されたパーソナルクレンジング組成物 |
CN103458858B (zh) | 2011-04-07 | 2016-04-27 | 宝洁公司 | 具有增强的聚丙烯酸酯微胶囊的沉积的洗发剂组合物 |
CN103458871B (zh) | 2011-04-07 | 2015-05-13 | 宝洁公司 | 具有增强的聚丙烯酸酯微胶囊的沉积的调理剂组合物 |
KR20140147891A (ko) | 2012-04-13 | 2014-12-30 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | 응집체 입자 |
CN104519884A (zh) | 2012-06-15 | 2015-04-15 | 公益财团法人先端医疗振兴财团 | 轻度认知障碍的预防和/或治疗剂 |
ES2717469T3 (es) | 2012-08-15 | 2019-06-21 | Tris Pharma Inc | Comprimido masticable de metilfenidato de liberación prolongada |
WO2014057059A1 (en) | 2012-10-11 | 2014-04-17 | Sanovel Ilac Sanayi Ve Ticaret A.S. | Effervescent cefdinir formulation |
CN103848986B (zh) * | 2012-11-28 | 2019-10-11 | 杨子剑 | 含有头孢菌素结构的化合物以及制备方法和用途 |
EP2815743A1 (en) | 2013-06-21 | 2014-12-24 | Sanovel Ilac Sanayi ve Ticaret A.S. | Ceftibuten formulations |
CN103637992B (zh) * | 2013-12-19 | 2015-04-08 | 石家庄市华新药业有限责任公司 | 一种头孢地尼颗粒制剂及其制备方法 |
RU2561683C1 (ru) * | 2014-03-26 | 2015-08-27 | Александр Александрович Кролевец | Способ получения нанокапсул цефалоспориновых антибиотиков в альгинате натрия |
US11590228B1 (en) | 2015-09-08 | 2023-02-28 | Tris Pharma, Inc | Extended release amphetamine compositions |
US11590081B1 (en) | 2017-09-24 | 2023-02-28 | Tris Pharma, Inc | Extended release amphetamine tablets |
Family Cites Families (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4330626A (en) * | 1980-03-19 | 1982-05-18 | The Enzyme Center, Inc. | Method of preparing high-activity, low-bacteria, urease enzyme |
US4826689A (en) * | 1984-05-21 | 1989-05-02 | University Of Rochester | Method for making uniformly sized particles from water-insoluble organic compounds |
US4783484A (en) * | 1984-10-05 | 1988-11-08 | University Of Rochester | Particulate composition and use thereof as antimicrobial agent |
IE58110B1 (en) * | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
FR2634376B1 (fr) * | 1988-07-21 | 1992-04-17 | Farmalyoc | Nouvelle forme unitaire, solide et poreuse comprenant des microparticules et/ou des nanoparticules, ainsi que sa preparation |
US5145684A (en) * | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
US5399363A (en) * | 1991-01-25 | 1995-03-21 | Eastman Kodak Company | Surface modified anticancer nanoparticles |
US5552160A (en) * | 1991-01-25 | 1996-09-03 | Nanosystems L.L.C. | Surface modified NSAID nanoparticles |
AU642066B2 (en) * | 1991-01-25 | 1993-10-07 | Nanosystems L.L.C. | X-ray contrast compositions useful in medical imaging |
NZ248813A (en) * | 1992-11-25 | 1995-06-27 | Eastman Kodak Co | Polymeric grinding media used in grinding pharmaceutical substances |
US5349957A (en) * | 1992-12-02 | 1994-09-27 | Sterling Winthrop Inc. | Preparation and magnetic properties of very small magnetite-dextran particles |
US5346702A (en) * | 1992-12-04 | 1994-09-13 | Sterling Winthrop Inc. | Use of non-ionic cloud point modifiers to minimize nanoparticle aggregation during sterilization |
US5298262A (en) * | 1992-12-04 | 1994-03-29 | Sterling Winthrop Inc. | Use of ionic cloud point modifiers to prevent particle aggregation during sterilization |
US5302401A (en) * | 1992-12-09 | 1994-04-12 | Sterling Winthrop Inc. | Method to reduce particle size growth during lyophilization |
US5340564A (en) * | 1992-12-10 | 1994-08-23 | Sterling Winthrop Inc. | Formulations comprising olin 10-G to prevent particle aggregation and increase stability |
US5336507A (en) * | 1992-12-11 | 1994-08-09 | Sterling Winthrop Inc. | Use of charged phospholipids to reduce nanoparticle aggregation |
US5429824A (en) * | 1992-12-15 | 1995-07-04 | Eastman Kodak Company | Use of tyloxapole as a nanoparticle stabilizer and dispersant |
US5352459A (en) * | 1992-12-16 | 1994-10-04 | Sterling Winthrop Inc. | Use of purified surface modifiers to prevent particle aggregation during sterilization |
US5326552A (en) * | 1992-12-17 | 1994-07-05 | Sterling Winthrop Inc. | Formulations for nanoparticulate x-ray blood pool contrast agents using high molecular weight nonionic surfactants |
US5401492A (en) * | 1992-12-17 | 1995-03-28 | Sterling Winthrop, Inc. | Water insoluble non-magnetic manganese particles as magnetic resonance contract enhancement agents |
US5264610A (en) * | 1993-03-29 | 1993-11-23 | Sterling Winthrop Inc. | Iodinated aromatic propanedioates |
US5525328A (en) * | 1994-06-24 | 1996-06-11 | Nanosystems L.L.C. | Nanoparticulate diagnostic diatrizoxy ester X-ray contrast agents for blood pool and lymphatic system imaging |
US5587143A (en) * | 1994-06-28 | 1996-12-24 | Nanosystems L.L.C. | Butylene oxide-ethylene oxide block copolymer surfactants as stabilizer coatings for nanoparticle compositions |
US5466440A (en) * | 1994-12-30 | 1995-11-14 | Eastman Kodak Company | Formulations of oral gastrointestinal diagnostic X-ray contrast agents in combination with pharmaceutically acceptable clays |
US5585108A (en) * | 1994-12-30 | 1996-12-17 | Nanosystems L.L.C. | Formulations of oral gastrointestinal therapeutic agents in combination with pharmaceutically acceptable clays |
US5560932A (en) * | 1995-01-10 | 1996-10-01 | Nano Systems L.L.C. | Microprecipitation of nanoparticulate pharmaceutical agents |
US5569448A (en) * | 1995-01-24 | 1996-10-29 | Nano Systems L.L.C. | Sulfated nonionic block copolymer surfactants as stabilizer coatings for nanoparticle compositions |
US5560931A (en) * | 1995-02-14 | 1996-10-01 | Nawosystems L.L.C. | Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids |
US5571536A (en) * | 1995-02-06 | 1996-11-05 | Nano Systems L.L.C. | Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids |
US5593657A (en) * | 1995-02-09 | 1997-01-14 | Nanosystems L.L.C. | Barium salt formulations stabilized by non-ionic and anionic stabilizers |
US5622938A (en) * | 1995-02-09 | 1997-04-22 | Nano Systems L.L.C. | Sugar base surfactant for nanocrystals |
US5534270A (en) * | 1995-02-09 | 1996-07-09 | Nanosystems Llc | Method of preparing stable drug nanoparticles |
US5518738A (en) * | 1995-02-09 | 1996-05-21 | Nanosystem L.L.C. | Nanoparticulate nsaid compositions |
US5591456A (en) * | 1995-02-10 | 1997-01-07 | Nanosystems L.L.C. | Milled naproxen with hydroxypropyl cellulose as a dispersion stabilizer |
US5500204A (en) * | 1995-02-10 | 1996-03-19 | Eastman Kodak Company | Nanoparticulate diagnostic dimers as x-ray contrast agents for blood pool and lymphatic system imaging |
US5573783A (en) * | 1995-02-13 | 1996-11-12 | Nano Systems L.L.C. | Redispersible nanoparticulate film matrices with protective overcoats |
US5510118A (en) * | 1995-02-14 | 1996-04-23 | Nanosystems Llc | Process for preparing therapeutic compositions containing nanoparticles |
US5543133A (en) * | 1995-02-14 | 1996-08-06 | Nanosystems L.L.C. | Process of preparing x-ray contrast compositions containing nanoparticles |
US5580579A (en) * | 1995-02-15 | 1996-12-03 | Nano Systems L.L.C. | Site-specific adhesion within the GI tract using nanoparticles stabilized by high molecular weight, linear poly (ethylene oxide) polymers |
US5565188A (en) * | 1995-02-24 | 1996-10-15 | Nanosystems L.L.C. | Polyalkylene block copolymers as surface modifiers for nanoparticles |
US5472683A (en) * | 1995-03-09 | 1995-12-05 | Eastman Kodak Company | Nanoparticulate diagnostic mixed carbamic anhydrides as X-ray contrast agents for blood pool and lymphatic system imaging |
US5573749A (en) * | 1995-03-09 | 1996-11-12 | Nano Systems L.L.C. | Nanoparticulate diagnostic mixed carboxylic anhydrides as X-ray contrast agents for blood pool and lymphatic system imaging |
US5521218A (en) * | 1995-05-15 | 1996-05-28 | Nanosystems L.L.C. | Nanoparticulate iodipamide derivatives for use as x-ray contrast agents |
US5573750A (en) * | 1995-05-22 | 1996-11-12 | Nanosystems L.L.C. | Diagnostic imaging x-ray contrast agents |
ES2231369T3 (es) * | 1996-02-29 | 2005-05-16 | Fujisawa Pharmaceutical Co., Ltd. | Granulo de disgregacion rapida de un edulcorante sintetico que contiene acido silicico y/o dioxido de silicio. |
AU1150799A (en) * | 1997-10-10 | 1999-05-03 | Yamanouchi Europe B.V. | Oral compositions containing a cephalosporin antibiotic |
DE19835823A1 (de) * | 1998-08-10 | 1999-10-07 | Lindopharm Gmbh | Pharmazeutische Zusammensetzung, Verfahren zu ihrer Herstellung und ihre Verwendung sowie aus ihr hergestellte wässerige Suspension |
US6248363B1 (en) * | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
EP1136080A3 (en) * | 2000-03-14 | 2002-06-05 | Pfizer Products Inc. | Use of o-vanillin and o-vanillin/trolox combinations |
CA2423336C (en) * | 2000-09-20 | 2011-03-08 | Rtp Pharma Inc. | Stabilised fibrate microparticles |
US20030054042A1 (en) * | 2001-09-14 | 2003-03-20 | Elaine Liversidge | Stabilization of chemical compounds using nanoparticulate formulations |
JP4464129B2 (ja) * | 2001-09-19 | 2010-05-19 | エラン ファーマ インターナショナル,リミティド | ナノ粒子インスリン製剤 |
MXPA05012821A (es) * | 2003-05-28 | 2006-02-13 | Nektar Therapeutics | Formulacion farmaceutica que comprende un agente activo insoluble en agua. |
US20050131079A1 (en) * | 2003-12-10 | 2005-06-16 | Pujara Chetan P. | Cefdinir oral suspension |
IL160095A0 (en) * | 2004-01-28 | 2004-06-20 | Yissum Res Dev Co | Formulations for poorly soluble drugs |
EP1771158A4 (en) * | 2004-07-02 | 2008-03-12 | Advancis Pharmaceutical Corp | TABLET FOR PULSED DELIVERY |
-
2006
- 2006-06-30 US US11/478,891 patent/US20070160675A1/en not_active Abandoned
-
2007
- 2007-06-21 ZA ZA200704744A patent/ZA200704744B/en unknown
- 2007-06-24 IL IL184174A patent/IL184174A0/en unknown
- 2007-06-26 NO NO20073289A patent/NO20073289L/no not_active Application Discontinuation
- 2007-06-26 AU AU2007202941A patent/AU2007202941A1/en not_active Abandoned
- 2007-06-27 MX MX2007007942A patent/MX2007007942A/es unknown
- 2007-06-28 CA CA002592727A patent/CA2592727A1/en not_active Abandoned
- 2007-06-29 BR BRPI0705488-2A patent/BRPI0705488A/pt not_active Application Discontinuation
- 2007-06-29 CN CNA200710152657XA patent/CN101259106A/zh active Pending
- 2007-06-29 EA EA200701195A patent/EA200701195A1/ru unknown
- 2007-06-29 KR KR1020070065588A patent/KR20080002689A/ko not_active Application Discontinuation
- 2007-06-29 SG SG200704898-6A patent/SG138592A1/en unknown
- 2007-07-02 EP EP07252670A patent/EP1905432A1/en not_active Withdrawn
- 2007-07-02 JP JP2007173663A patent/JP2008013562A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
SG138592A1 (en) | 2008-01-28 |
ZA200704744B (en) | 2010-04-28 |
BRPI0705488A (pt) | 2008-09-16 |
CN101259106A (zh) | 2008-09-10 |
MX2007007942A (es) | 2009-02-17 |
NO20073289L (no) | 2008-01-02 |
JP2008013562A (ja) | 2008-01-24 |
AU2007202941A1 (en) | 2008-01-17 |
US20070160675A1 (en) | 2007-07-12 |
IL184174A0 (en) | 2008-01-20 |
KR20080002689A (ko) | 2008-01-04 |
CA2592727A1 (en) | 2007-12-30 |
EP1905432A1 (en) | 2008-04-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA200701195A1 (ru) | Содержащие цефалоспорин композиции с наночастицами и с контролируемым высвобождением | |
NZ701559A (en) | Compositions comprising povidone-iodine | |
NZ593343A (en) | Combination cancer treatment conprising Abraxane and an inflamatory inhibitor | |
SG170047A1 (en) | Nanoparticulate posaconazole formulations | |
EP2638905A3 (en) | Biofilm treatment | |
WO2008092006A3 (en) | Antimicrobial compositions | |
WO2010030180A3 (en) | Peptide formulations and uses thereof | |
EA201390409A1 (ru) | Составы с низкой дозой панкрелипазы и кишечно-растворимым покрытием | |
NZ604029A (en) | Methods of treating bladder cancer | |
MX2019013701A (es) | Metodos para mejorar suministro de farmacos y efectividad de agentes terapeuticos. | |
WO2008089268A3 (en) | Methods and compositions for treating conditions associated with infection and/or inflammation | |
WO2008089310A3 (en) | Delta 5 desaturase inhibitors for the treatment of obesity | |
NZ606825A (en) | Methods and compositions for treating complement-associated disorders | |
MX2010002498A (es) | Metodos para tratar o prevenir la infeccion del tracto respiratorio que comprende la administracion de colecalciferol. | |
WO2007070677A3 (en) | Pharmaceutical compositions and methods for treating or preventing oxalate-related disease | |
EA200702518A1 (ru) | Композиции на основе наночастиц и с контролируемым высвобождением, включающие цефалоспорин | |
WO2006078424A3 (en) | Polyherbal compositions and methods for treating viral infections | |
MY155299A (en) | Oral dosage composition | |
JP2008534503A5 (ru) | ||
CA2632207C (en) | Use of calcitonin for the treatment of ra | |
WO2007112272A3 (en) | Formulations of low dose diclofenac and beta-cyclodextrin | |
EA200800092A1 (ru) | Композиции в виде наночастиц и с контролируемым высвобождением, включающие арил-гетероциклические соединения | |
WO2008112773A3 (en) | Droxidopa and pharmaceutical composition thereof for the treatment of neurally mediated hypotension | |
AU2009246603A8 (en) | Von willebrand factor (vwf) inhibitors for treatment or prevention of infarction | |
TW200719903A (en) | Compositions for the treatment of neoplasms |